GeneDx

GeneDx Holdings (WGS.US) closed at $68.02, down 5.14% from the previous close of $71.71, driven by persistent market concerns over widened Q1 losses and multiple securities class-action lawsuits. Q1 EPS was -$2.1584 (yoy -830%), operating loss of -$26.184 million (yoy -475%), and net profit margin fell to -61.92%, with deteriorating profitability weighing on the stock. The stock opened at $72.00, hit an intraday high of $72.405, then declined steadily to $68.02, now 60.19% below its 52-week high of $170.87. Despite a YTD drop of 48.59%, the closing price remains above its MA20 ($61.111) and MA60 ($56.636), suggesting near-term technical support. News-wise, the appointment of Mark Gardner as President on June 30 aims to scale the genomics business. However, the August 3 deadline for the securities fraud class action continues to overhang sentiment.